FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311744558> ?p ?o ?g. }

• W4311744558 abstract "Abstract Background A constellation of debilitating symptoms, known as post-acute sequelae of COVID-19 (PASC), has been described in those in those with prior SARS-CoV-2 infection. While SARS-CoV-2 vaccination remains an effective way to prevent severe illness, PASC in individuals infected after vaccination is not well characterized. Methods A cohort of adults with laboratory confirmed SARS-CoV-2 infection were enrolled as cases and longitudinally followed between March 2020-March 2022 in the greater Seattle region. Demographic and acute illness surveys capturing baseline symptoms, infection severity and medical care were administered at enrollment (Table). Controls with no history of SARS-CoV-2 infection were concurrently followed. Symptom surveys were given at 6 months post-infection. Vaccination status was self-reported. We defined PASC as the presence of one or more symptoms that persisted for at least 4 weeks after acute SARS-CoV-2 infection. Table.Demographic and Illness Characteristics of Study Participants*Days since illness onset refers to the days passed since infection date. **Comorbidities included hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cardiovascular disease, chronic liver disease, chronic kidney disease, HIV, current use of immunosuppressants or diagnosis of cancer. Results Of 369 cases and 93 controls 57% (median age 44.7 years; 59.3% female) and 30% (median age 50.0 years; 50.0% female), completed the 6-month survey, respectively (Table). A total of 174 cases were infected prior to vaccination and 35 were post-vaccination. A total of 58 (28%) cases reported symptoms at 6 months, compared to 5 (18%) controls (Figure). In participants infected pre-vaccination, 32% reported PASC symptoms, compared to 6% of those infected post-vaccination (Figure; P=0.001). Conclusion Our study found that the proportion of individuals reporting PASC at 6 months after infection was significantly higher among those infected before SARS-CoV-2 vaccination than those who were infected after. This suggests that timing of vaccination relative to SARS-CoV-2 infection may be associated with the development of PASC symptoms. Symptoms were still reported among many individuals with PASC who were vaccinated after their infection. Further research is required to understand the underlying mechanisms of PASC, and to characterize PASC in those infected after vaccination and with variant of concerns. Disclosures Helen Y. Chu, MD, MPH, Cepheid: Reagents|Ellume: Advisor/Consultant|Gates Ventures: Grant/Research Support|Merck: Advisor/Consultant|Pfizer: Advisor/Consultant." @default.
• W4311744558 created "2022-12-28" @default.
• W4311744558 creator A5010481613 @default.
• W4311744558 creator A5021510904 @default.
• W4311744558 creator A5027759677 @default.
• W4311744558 creator A5030772339 @default.
• W4311744558 creator A5047880468 @default.
• W4311744558 creator A5053484297 @default.
• W4311744558 creator A5091204011 @default.
• W4311744558 date "2022-12-01" @default.
• W4311744558 modified "2023-10-14" @default.
• W4311744558 title "1054. Comparison of Post-Acute COVID-19 Symptoms in Infected Individuals Pre- and Post-Vaccination" @default.
• W4311744558 doi "https://doi.org/10.1093/ofid/ofac492.895" @default.
• W4311744558 hasPublicationYear "2022" @default.
• W4311744558 type Work @default.
• W4311744558 citedByCount "0" @default.
• W4311744558 crossrefType "journal-article" @default.
• W4311744558 hasAuthorship W4311744558A5010481613 @default.
• W4311744558 hasAuthorship W4311744558A5021510904 @default.
• W4311744558 hasAuthorship W4311744558A5027759677 @default.
• W4311744558 hasAuthorship W4311744558A5030772339 @default.
• W4311744558 hasAuthorship W4311744558A5047880468 @default.
• W4311744558 hasAuthorship W4311744558A5053484297 @default.
• W4311744558 hasAuthorship W4311744558A5091204011 @default.
• W4311744558 hasBestOaLocation W43117445581 @default.
• W4311744558 hasConcept C126322002 @default.
• W4311744558 hasConcept C134018914 @default.
• W4311744558 hasConcept C187212893 @default.
• W4311744558 hasConcept C203014093 @default.
• W4311744558 hasConcept C22070199 @default.
• W4311744558 hasConcept C2779134260 @default.
• W4311744558 hasConcept C555293320 @default.
• W4311744558 hasConcept C71924100 @default.
• W4311744558 hasConcept C72563966 @default.
• W4311744558 hasConceptScore W4311744558C126322002 @default.
• W4311744558 hasConceptScore W4311744558C134018914 @default.
• W4311744558 hasConceptScore W4311744558C187212893 @default.
• W4311744558 hasConceptScore W4311744558C203014093 @default.
• W4311744558 hasConceptScore W4311744558C22070199 @default.
• W4311744558 hasConceptScore W4311744558C2779134260 @default.
• W4311744558 hasConceptScore W4311744558C555293320 @default.
• W4311744558 hasConceptScore W4311744558C71924100 @default.
• W4311744558 hasConceptScore W4311744558C72563966 @default.
• W4311744558 hasIssue "Supplement_2" @default.
• W4311744558 hasLocation W43117445581 @default.
• W4311744558 hasLocation W43117445582 @default.
• W4311744558 hasOpenAccess W4311744558 @default.
• W4311744558 hasPrimaryLocation W43117445581 @default.
• W4311744558 hasRelatedWork W1563850031 @default.
• W4311744558 hasRelatedWork W2045367862 @default.
• W4311744558 hasRelatedWork W2074686124 @default.
• W4311744558 hasRelatedWork W2315085516 @default.
• W4311744558 hasRelatedWork W2316407790 @default.
• W4311744558 hasRelatedWork W2415759662 @default.
• W4311744558 hasRelatedWork W2603773853 @default.
• W4311744558 hasRelatedWork W2884196303 @default.
• W4311744558 hasRelatedWork W2964295425 @default.
• W4311744558 hasRelatedWork W3036934084 @default.
• W4311744558 hasVolume "9" @default.
• W4311744558 isParatext "false" @default.
• W4311744558 isRetracted "false" @default.
• W4311744558 workType "article" @default.